Exploiting the folate receptor α in oncology

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Folate receptor alpha (FRα) is overexpressed in various solid tumors, including ovarian, lung, and breast cancers.
• FRα-mediated folate uptake is a key cellular process exploited by cancer cells.
• Traditional intracellular folate metabolism drugs exist, but FRα presents a distinct targeting opportunity.

Purpose of the Study:

• To review the current research status of folate receptor alpha (FRα) in oncology.
• To discuss the potential of FRα-targeted therapies and diagnostic tools in cancer treatment.
• To highlight advancements in developing novel FRα-targeting agents.

Main Methods:

• Review of existing literature and clinical trial data on FRα-targeted therapies.
• Analysis of FRα's role in cancer cell uptake and its potential as a drug target.
• Examination of emerging technologies for FRα-based drug delivery and imaging.

Main Results:

• FRα overexpression in solid tumors makes it an attractive target for anticancer drugs.
• Various platforms like antibody-drug conjugates and CAR T-cells are being developed to target FRα.
• FRα also serves as a predictive biomarker and can be used for improved imaging and surgical guidance.

Conclusions:

• FRα-targeted therapies, including those in late-phase clinical trials, hold significant promise for improving outcomes in FRα-overexpressing cancers.
• New technologies are enabling the development of FRα-targeted agents with enhanced therapeutic indices.
• The multifaceted role of FRα in cancer necessitates continued research for optimized therapeutic and diagnostic strategies.